Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2021 | Racial disparities: American patients with AML

Paresh Vyas • 27 Apr 2021
BSH 2021
Acute Myeloid Leukemia General Leukemia

Paresh Vyas, MRCP, FRCP, FRCPath, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK, outlines a retrospective review detailing poorer healthcare outcomes for black patients compared to white patients in the US. Whilst the review had methodological limitations, there were clear disparities in healthcare outcomes, regardless of access to healthcare. Prof. Vyas suggests collecting data from a more diverse population in terms of ethnicity, socioeconomic status, and access to healthcare and education to accurately reflect outcome disparities. He additionally suggests the undertaking of a similar study in the UK. This interview took place at the 2021 British Society for Haematology Annual Scientific Meeting.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Paresh Vyas

Current challenges in clinical genomics
Current challenges in clinical genomics
Andrew Wei et al. • 29 Sep 2022
What do we know about drug resistance in AML?
What do we know about drug resistance in AML?
Alexander Perl et al. • 29 Sep 2022
Promising emerging therapies for AML and the challenges that remain
2:45
Promising emerging therapies for AML and the challenges that remain
Paresh Vyas • 18 Dec 2023
First-in-human study of the menin-KMT2A inhibitor JNJ-75276617 in R/R acute leukemias
6:11
First-in-human study of the menin-KMT2A inhibitor JNJ-75276617 in R/R acute leukemias
Paresh Vyas • 18 Dec 2023

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals